about
Update and new approaches in the treatment of Castleman diseasePotential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosisPotential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancerTargeted Therapies in Adult B-Cell MalignanciesReview of siltuximab in the treatment of multicentric Castleman's diseaseIntegrating Interleukin-6 into depression diagnosis and treatmentAnemia of Inflammation: A Review.From obesity to cancer: a review on proposed mechanisms.Desensitization: Overcoming the Immunologic Barriers to TransplantationSiltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trialA phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosisMeasuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts.Genetic characterization of interleukins (IL-1α, IL-1β, IL-2, IL-4, IL-8, IL-10, IL-12A, IL-12B, IL-15 and IL-18) with relevant biological roles in lagomorphs.Malignancies in systemic lupus erythematosus: a 2015 update.Immunoinflammatory diseases of the central nervous system - the tale of two cytokines.Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment.Impaired lymphatic function accelerates cancer growth.The microRNA miR-33a suppresses IL-6-induced tumor progression by binding Twist in gallbladder cancer.The tumor microenvironment promotes cancer progression and cell migration.Probing binding mechanism of interleukin-6 and olokizumab: in silico design of potential lead antibodies for autoimmune and inflammatory diseases.Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.lnflammation-induced epigenetic switches in cancer.CURRENT CONCEPTS ON THE GENETIC FACTORS IN ROTATOR CUFF PATHOLOGY AND FUTURE IMPLICATIONS FOR SPORTS PHYSICAL THERAPISTS.Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells.Glutathione in metastases: From mechanisms to clinical applications.Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.Soluble IL6R represents a miR-34a target: potential implications for the recently identified IL-6R/STAT3/miR-34a feed-back loop.Differential Mechanisms of Inflammation and Endothelial Dysfunction by HIV-1 Subtype-B and Recombinant CRF02_AG Tat Proteins on Human Brain Microvascular Endothelial Cells: Implications for Viral Neuropathogenesis.Nanosized UCMSC-derived extracellular vesicles but not conditioned medium exclusively inhibit the inflammatory response of stimulated T cells: implications for nanomedicine.Differential in vivo activation of monocyte subsets during low-grade inflammation through experimental endotoxemia in humans.CXCL1, but not IL-6, significantly impacts intraocular inflammation during infection.Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma15-Deoxy-Δ(12,14)-prostaglandin J2 Induces Apoptosis and Upregulates SOCS3 in Human Thyroid Cancer Cells.Contribution of neuroblastoma-derived exosomes to the production of pro-tumorigenic signals by bone marrow mesenchymal stromal cellsRegulatory Role of the MicroRNA-29b-IL-6 Signaling in the Formation of Vascular Mimicry.The impact of thyroid hormones on patients with hepatocellular carcinoma.Development and validation of panoptic Meso scale discovery assay to quantify total systemic interleukin-6.Serum Interleukin-6 Levels and Pulmonary Function in Ataxia-Telangiectasia.Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism.
P2860
Q26740703-31940331-8BA3-494E-B9E9-9A999680C045Q26746099-A197E72A-EB65-4FAB-9073-7570A214FC9DQ26769917-D4C63290-4A8D-4CED-9C21-7102A7A2EBA5Q26783195-6F8E5AA0-5CDA-4C84-AF74-497A11A3D783Q28067246-7ACC804F-B029-41CC-9490-A9B61D72B8EEQ28070891-98532886-12D9-4753-AB0A-9306DD7C482FQ30235957-69D3B01B-7326-4292-B2C3-F3A05095AB4DQ30241069-5988E572-150F-4646-A472-2100DC74CA22Q30397952-AD911A5D-34C6-468C-8175-0971DC31406CQ33429980-F783CBFF-237A-457F-952D-0A09B4A08BF3Q33434284-4FC12C18-6582-4857-9133-5FAA2E76D37CQ33851168-D9AE46F9-46C3-4BD0-B11F-908CE3AC3DC5Q34530301-CC84FD4E-30C2-4366-B359-A4CC6D5E675BQ35784301-48AE49D1-DBD7-4A73-85A1-14024FFDDD28Q36035448-6766260B-E20F-43FF-A84F-8F444ACDD3A4Q36547012-07D8E5A2-FB1C-4398-9ECB-928EC6BD0C26Q36797297-3516AFC7-83E3-48AF-B716-81AC2CC091E1Q37564556-1E9C359A-8C2E-41B4-A6FA-24AA8F85638AQ37694682-AE821E7B-F8FE-4285-9101-C109247E6DCFQ37706031-FDF4566B-5B59-4D32-9BEC-CFCEAD5016C6Q38382090-B59E9163-A420-469A-A5FC-3E28DFF747AAQ38591052-53803C8C-2E2D-4681-BD65-3A68BF999383Q38591056-DCC3EEFF-BE06-4D96-B40B-6297BA81C291Q38682601-9EFEB03F-5326-4121-A25B-1FA13E27F6F6Q38688878-2A239CED-851F-4190-AD70-5284DAB2C0EBQ38692702-04EFF6EC-21CB-432D-874F-3C7D828B8E73Q38756385-076A5A88-2098-4E0E-8917-B21AA710765DQ38862169-E0D2B605-F0CF-491A-9EF1-2D0B8D06B2C0Q38996141-BC488B20-ADA1-478F-9A98-56613DDF8A93Q39044765-D495E7D9-9C79-4A92-999E-D97E1F21170BQ39573678-9485ED07-7141-4620-ACD5-C30FD574AEA2Q40473896-F0521DE0-CBBC-4979-BFD5-84560F151FA3Q40696725-14328F59-AEDB-4994-B28F-37EAA8EBBBD2Q40845153-A625BC05-7084-4F7A-BB54-1E8819220AAFQ40980101-F0334356-1F97-4A4A-9363-820DB75BF545Q40984509-DC05EE25-8755-4E7E-8B5C-6688933B3BC8Q41237536-7BA20D4F-61D1-498F-9D13-6E96E54F2375Q41266576-83392268-1B50-414B-A136-167F8EDB8B5FQ41456647-FDF3E1D2-C42D-43C8-8345-50DAD32A8EFDQ41585035-D1DF388E-A53D-429F-9EC6-5FE0EAAE55AF
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Interleukin-6 as a therapeutic target.
@en
type
label
Interleukin-6 as a therapeutic target.
@en
prefLabel
Interleukin-6 as a therapeutic target.
@en
P2093
P1476
Interleukin-6 as a therapeutic target.
@en
P2093
Bernard Klein
Jean-François Rossi
Michel Jourdan
Zhao-Yang Lu
P304
P356
10.1158/1078-0432.CCR-14-2291
P407
P577
2015-01-14T00:00:00Z